Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ViroPharma gains on Vancocin sales update

ViroPharma (NASDAQ:VPHM) was up $0.68

Read the full 55 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE